Hepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but
is preventable. HBV reactivation is most commonly reported in patients receiving …

Although a pathogenic role for the Epstein-Barr virus (EBV) is largely undisputed for tumors
that are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt …

With the recent approvals for the application of monoclonal antibodies that target the well-
characterized immune checkpoints, immune therapy shows great potential against both …

Background: The tumor microenvironment (TME) of human glioblastoma (GBM) exhibits
considerable immune cell infiltration, and such cell types have been shown to be widely …

Tumor microenvironment and immune escape affect pathogenesis and survival in classical
Hodgkin lymphoma (cHL). While tumor-associated macrophage (TAM) content has been …

Abstract Anti-PD-1/PD-L1 immunotherapy, as a treatment for many tumors, has shown good
efficacy. However, responses to immunotherapy did not always occur or last long., ie primary …

Cardiovascular (CV) diseases and cancer are the leading causes of death in Europe and
the United States. Both diseases have extensive overlap and share common risk factors …

Background: Programmed cell death protein 1 (PD1) inhibitors have revolutionized cancer
therapy, yet many patients fail to respond. Thus, the identification of accurate predictive …

Simple Summary Drug resistance is an obstacle to cancer therapy, and the underlying
mechanisms are still being explored. CC chemokine ligand-2 (CCL2) is one of the key …

Epstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated
lymphoproliferative diseases (EBV-LPDs) ranging from post-transplant lymphoproliferative …